Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.88 |
| ▸ | HDAC3 | O15379 | 19/20 | 0.88 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.88 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.88 |
| ▸ | HDAC4 | P56524 | 18/20 | 0.88 |
| ▸ | HDAC7 | Q8WUI4 | 18/20 | 0.88 |
| ▸ | HDAC10 | Q969S8 | 18/20 | 0.88 |
| ▸ | HDAC11 | Q96DB2 | 18/20 | 0.88 |
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.88 |
| ▸ | HDAC9 | Q9UKV0 | 18/20 | 0.88 |
| ▸ | HDAC5 | Q9UQL6 | 18/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641357 | 0.97 | HDAC3 (0.87) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL2568461 | 0.93 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL2641235 | 0.92 | HDAC3 (0.87) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL3289437 | 0.90 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL12999351 | 0.88 | HDAC1 (0.94) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL2569059 | 0.86 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL3288305 | 0.86 | HDAC3 (0.86) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL2567384 | 0.85 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL2566576 | 0.84 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| SCHEMBL12999344 | 0.83 | HDAC3 (0.81) | HDAC1HDAC3HDAC2HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723376-B2 | 2-oxo-heterocyclic compounds and pharmaceutical compositions | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-05-25 | — | — | US | disclosed |
| US-7723376-B2 | 2-oxo-heterocyclic compounds and pharmaceutical compositions | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-05-25 | — | — | US | disclosed |
| US-7723376-B2 | 2-oxo-heterocyclic compounds and pharmaceutical compositions | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-05-25 | — | — | US | disclosed |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-08-03 | — | — | US | disclosed |
| EP-1663201-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005004861-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | MALT1, BRCA1, MCL1 | HDAC1 2103/4885HDAC3 2001/4885HDAC2 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.